These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25267665)

  • 21. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
    Garneau JR; Valiquette L; Fortier LC
    BMC Infect Dis; 2014 Jan; 14():29. PubMed ID: 24422950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high-throughput small-molecule screen to identify a novel chemical inhibitor of Clostridium difficile.
    Katzianer DS; Yano T; Rubin H; Zhu J
    Int J Antimicrob Agents; 2014 Jul; 44(1):69-73. PubMed ID: 24837414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
    Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW
    Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the economics of treating Clostridium difficile infection.
    Mergenhagen KA; Wojciechowski AL; Paladino JA
    Pharmacoeconomics; 2014 Jul; 32(7):639-50. PubMed ID: 24807468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.
    Spinler JK; Brown A; Ross CL; Boonma P; Conner ME; Savidge TC
    Anaerobe; 2016 Aug; 40():54-7. PubMed ID: 27180007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole.
    Lu CL; Liu CY; Liao CH; Huang YT; Wang HP; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):311-2. PubMed ID: 20045292
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
    Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
    Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
    Sholeh M; Krutova M; Forouzesh M; Mironov S; Sadeghifard N; Molaeipour L; Maleki A; Kouhsari E
    Antimicrob Resist Infect Control; 2020 Sep; 9(1):158. PubMed ID: 32977835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection.
    O'Donnell JN; Novak GM; Bratek BR; Singh G; Duru OO; Mitchell CL; Roddy KM; Bidell MR
    Int J Antimicrob Agents; 2021 Apr; 57(4):106311. PubMed ID: 33621602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study.
    Bishop EJ; Tiruvoipati R; Metcalfe J; Marshall C; Botha J; Kelley PG
    Intern Med J; 2018 Jun; 48(6):651-660. PubMed ID: 29363242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Piglet models of acute or chronic Clostridium difficile illness.
    Steele J; Feng H; Parry N; Tzipori S
    J Infect Dis; 2010 Feb; 201(3):428-34. PubMed ID: 20039803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel agent effective against Clostridium difficile infection.
    Dvoskin S; Xu WC; Brown NC; Yanachkov IB; Yanachkova M; Wright GE
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1624-6. PubMed ID: 22203600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized microbiota mice as a model of recurrent Clostridium difficile disease.
    Collins J; Auchtung JM; Schaefer L; Eaton KA; Britton RA
    Microbiome; 2015 Aug; 3():35. PubMed ID: 26289776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.
    Hota SS; Sales V; Tomlinson G; Salpeter MJ; McGeer A; Coburn B; Guttman DS; Low DE; Poutanen SM
    Clin Infect Dis; 2017 Feb; 64(3):265-271. PubMed ID: 28011612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of candidemia in patients with Clostridium difficile infection.
    Falcone M; Venditti M; Sanguinetti M; Posteraro B
    Expert Rev Anti Infect Ther; 2016 Jul; 14(7):679-85. PubMed ID: 27254270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of tigecycline in elderly patients for Clostridium difficile infection.
    Fantin F; Manica A; Soldani F; Bissoli L; Zivelonghi A; Zamboni M
    Geriatr Gerontol Int; 2015 Feb; 15(2):230-1. PubMed ID: 25619268
    [No Abstract]   [Full Text] [Related]  

  • 38. Recurrent Clostridium difficile infections: the importance of the intestinal microbiota.
    Zanella Terrier MC; Simonet ML; Bichard P; Frossard JL
    World J Gastroenterol; 2014 Jun; 20(23):7416-23. PubMed ID: 24966611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
    Di Bella S; Nisii C; Petrosillo N
    Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.